Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic - 09/11/20
Doi : 10.1016/j.jaad.2020.07.086
Donovan G. Kearns, BA a, Vipawee S. Chat, BS b, Shelley Uppal, MD c, Jashin J. Wu, MD d, ⁎ 
a Loma Linda University School of Medicine, Loma Linda, California
b Medical College of Georgia at Augusta University, Augusta, California
c Albany Medical College School of Medicine, Albany, New York
d Dermatology Research and Education Foundation, Irvine, California
∗Reprint requests: Jashin J. Wu, MD, Dermatology Research and Education Foundation, Irvine, CaliforniaDermatology Research and Education FoundationIrvineCalifornia92620
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Disclosure: Dr Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermavant, Dermira, Dr. Reddy's Laboratories, Eli Lilly, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, UCB, and Valeant Pharmaceuticals North America LLC. Drs Kearns, Chat, and Uppal have no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 6
P. e433-e434 - décembre 2020 Retour au numéro
Article précédent
- High placebo rates in clinical trials: Is the problem scoring systems or drug efficacy?
- Alexa B. Kimball
- Reply to: “The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanism”
- Raphael Carloni, Silvia Gandolfi, Francois Postel, Nicolas Bertheuil, Lolita Pechevy
Bienvenue sur EM-consulte, la référence des professionnels de santé.